Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Post by elgin1on Dec 29, 2020 11:32am
332 Views
Post# 32191387

Ladies time to change your panties.

Ladies time to change your panties. Update from newsletter writer . MMED CEO is from Uber ???? Six months ago, MindMed (MMEDF)'s market cap was US$65.13 million. Today, MMEDF's market cap is US$1.06 billion. MMEDF may be applying for patents but BETRF has already been awarded patents protecting its process that allows for cost-effective manufacturing of BOL-148 without the need to make LSD, making BETRF the only entity with the ability to synthesize the drug without the regulatory hurdles of handling a Schedule 1 controlled substance. MMEDF has an inexperienced management team (its CEO previously held a low level job at Uber). BETRF has a highly experienced and successful management team of industry experts.BETRF's CEO Dr. Ahmad Doroudian took the last company he founded Merus Labs to the NASDAQ where it was acquired in 2017 at a 65% premium that valued it at US$270 million.
<< Previous
Bullboard Posts
Next >>